SG11201908384XA - Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas - Google Patents

Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Info

Publication number
SG11201908384XA
SG11201908384XA SG11201908384XA SG11201908384XA SG 11201908384X A SG11201908384X A SG 11201908384XA SG 11201908384X A SG11201908384X A SG 11201908384XA SG 11201908384X A SG11201908384X A SG 11201908384XA
Authority
SG
Singapore
Prior art keywords
international
anchor
linker
cells
compositions
Prior art date
Application number
Inventor
Scott Dessain
Rama Puligedda
Original Assignee
Lankenau Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Inst Medical Res filed Critical Lankenau Inst Medical Res
Publication of SG11201908384XA publication Critical patent/SG11201908384XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) D IV o Ho inciummo iflo VII IE (10) International Publication Number WO 2018/175917 Al WIPO I PCT (51) International Patent Classification: C12N 15/02 (2006.01) C12N 15/09 (2006.01) C12N 15/08 (2006.01) (21) International Application Number: PCT/US2018/024073 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,599 24 March 2017 (24.03.2017) US 62/526,608 29 June 2017 (29.06.2017) US (71) Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCH [US/US]; 100 Lancaster Avenue, Wyn- newood, PA 19096 (US). (72) Inventors: DESSAIN, Scott, K.; 1370 Indian Creek Drive, Wynnewood, PA 19096 (US). PULIGEDDA, Rama, De- vudu; 941 South Avenue, Apt C2, Secane, PA 19018 (US). (74) Agent: BAK, Mary, E. et al.; Howson & Howson LLP, 350 Sentry Parkway, Building 620, Suite 210, Blue Bell, PA 19422 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS AND COMPOSITIONS FOR INDUCIBLE EXTRACELLULAR MEMBRANE CAPTURE OF MONO- CLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS N (57) : Compositions and methods are provided for making and using a cell having expressed on its outer plasma membrane surface an Anchor designed to form a first complex with a selected Linker. The Linker is designed to form a second complex with a target protein that is not recognized by the Anchor. These cells can be primary cells or immortalized cells, they function as fusion N partners to create hybridoma cells. The cells can be designed to bind a secreted targeted protein, e.g., a secreted antibody, to the cell surface via an immune complex formed by the Anchor-Linker and permit the identification of the existence, antigen specificity, and 00 antigen binding affinity, titer, amount, or biological activity of the target protein. In certain embodiments, the Linker is of a species O heterologous to the species of the Anchor; and the target protein is of a species heterologous to the Linker and to the Anchor. O
SG11201908384X 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas SG11201908384XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762476599P 2017-03-24 2017-03-24
US201762526608P 2017-06-29 2017-06-29
PCT/US2018/024073 WO2018175917A1 (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Publications (1)

Publication Number Publication Date
SG11201908384XA true SG11201908384XA (en) 2019-10-30

Family

ID=63584730

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908384X SG11201908384XA (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
SG10202110530WA SG10202110530WA (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202110530WA SG10202110530WA (en) 2017-03-24 2018-03-23 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas

Country Status (7)

Country Link
US (1) US11946074B2 (en)
EP (1) EP3601558A4 (en)
JP (1) JP7287940B2 (en)
CA (1) CA3056249A1 (en)
IL (1) IL269472A (en)
SG (2) SG11201908384XA (en)
WO (1) WO2018175917A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357787B2 (en) 2019-02-18 2022-06-14 Nb Health Laboratory Co., Ltd. Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376170B1 (en) 1994-10-03 2002-04-23 The Scripps Research Institute Ligand capture-directed selection of antibody
DE19900635A1 (en) 1999-01-11 2000-07-13 Deutsches Krebsforsch Selection of monoclonal antibodies
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
JP4323167B2 (en) 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Isolation of cells expressing secreted proteins
DE60238308D1 (en) 2001-02-20 2010-12-30 Univ Georgia QUICK PRODUCTION MONOCLONAL ANTIBODY
CN1856576B (en) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2009131605A2 (en) 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
EA201100943A1 (en) * 2008-12-16 2012-05-30 Новартис Аг YEAST DISPLAY SYSTEMS
KR20120117931A (en) * 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. Methods for identifying and isolating cells expressing a polypeptide
EP2390661B1 (en) 2010-05-02 2015-06-24 Miltenyi Biotec GmbH An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell
TWI675044B (en) 2012-11-14 2019-10-21 美商再生元醫藥公司 Recombinant cell surface capture proteins
TWI619727B (en) 2013-02-27 2018-04-01 中央研究院 In situ affinity maturation of antibodies
TWI588259B (en) 2015-03-06 2017-06-21 Methods for screening antigen-specific fusion tumor cells

Also Published As

Publication number Publication date
EP3601558A1 (en) 2020-02-05
CA3056249A1 (en) 2018-09-27
US11946074B2 (en) 2024-04-02
SG10202110530WA (en) 2021-11-29
IL269472A (en) 2019-11-28
JP2020515288A (en) 2020-05-28
EP3601558A4 (en) 2021-01-06
WO2018175917A1 (en) 2018-09-27
JP7287940B2 (en) 2023-06-06
US20200010810A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201909499QA (en) Humanized antigen-binding domains against cd19 and methods of use
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201906341XA (en) Improved serum albumin binders
SG11201906264YA (en) Improved serum albumin binders
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201407644UA (en) Methods for making fully human bispecific antibodies using a common light chain
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use